US Patent

US11053502 — Therapeutic inhibition of lactate dehydrogenase and agents therefor

Composition of Matter · Assigned to Dicerna Pharmaceuticals Inc · Expires 2035-10-29 · 9y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds and methods that use specific types of RNA to reduce levels of lactate dehydrogenase target RNA and protein.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

nedosiran-sodium (NEDOSIRAN SODIUM)

Patent Metadata

Patent number: US11053502
Jurisdiction: US
Classification: Composition of Matter
Expires: 2035-10-29
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dicerna Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.